WEHI New Medicines and Diagnostics Special Seminar hosted by Professor Guillaume Lessene

Dr Jonathan Hall and Dr Jun Zeng

Chief Executive Officer and Chief Information Officer – Qubigen Pty Ltd

We Build AI Engines for Drug Design with our Secure Federated Platform

L7W Seminar Room  | Bundoora Large Boardroom

Join via TEAMS

Including Q&A session

Qubigen’s FedAIDD system uses Federated AI to create advanced, disease-agnostic AI Engines for drug design, utilising data without transferring or accessing it directly. Built on a secure platform, it enables collaboration and delivers an end-to-end, application-specific workflow, producing actionable novel compounds for both classic and undruggable targets.

The platform accelerates hit-to-lead optimisation through secure analysis of molecular data, advanced virtual screening, GPU-parallelised quantum chemistry and the adaptable ability to select and curate the right data at arm’s length, tailoring compounds with specific ADMET properties.

Our case studies demonstrate Federated AI can make ‘cognitive leaps’ to design highly novel compounds that match or outperform traditional methods even on limited and otherwise untrainable datasets, can de-risk candidates by providing ADME-Tox analysis or synthetic feasibility, and can be developed at reduced SAR and downstream costs.

Dr Jonathan Hall is the CEO of Qubigen and pioneers Federated AI to conquer global health challenges through innovative drug design. The Founder of Life Whisperer (acquired 2024), he revolutionized IVF with AI, earning The MIT Technology Review ‘Innovators Under 35’ award, Talent Unleashed Global Winner of ‘One-to-Watch’, and Frost & Sullivan Global Leadership Awards. Dr. Hall has been featured in Time and Scientific American. He holds PhDs in Particle Physics (Quantum Chromodynamics) and Nanotech/BioPhotonics.

Dr Jun Zeng has over 25 years of experience in drug discovery and development across both academia and industry. After completing his PhD, he was awarded the prestigious C.J. Martin Fellowship from the NHMRC and subsequently worked at CNRS, France, the Ludwig Institute for Cancer Research, and Cytopia Ltd. Dr. Zeng played a key role in the original design of the kinase inhibitor Momelotinib, which was acquired by GSK for $1.9 billion in 2022 and received FDA approval in 2023. He currently serves as Chief Information Officer at Qubigen Pty Ltd and is a Fellow of the Royal Australian Chemical Institute

All welcome!